Salud financiera de hoja de balance de Intellia Therapeutics
Salud financiera controles de criterios 6/6
Intellia Therapeutics tiene unos fondos propios totales de $1.0B y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $1.2B y $205.9M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$912.22m |
| Patrimonio | US$1.05b |
| Total pasivo | US$250.81m |
| Activos totales | US$1.30b |
Actualizaciones recientes sobre salud financiera
Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07
Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation
Aug 01Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth
Apr 16Recent updates
Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Aug 31Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation
Aug 01Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Jul 05Intellia Makes History. Can It Deliver A Cure?
Jun 28Intellia Therapeutics Q1 2021 Earnings Preview
May 05Intellia Expands Its In Vivo Advantage
May 02Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth
Apr 16Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher
Mar 12Análisis de la situación financiera
Pasivos a corto plazo: NTLALos activos a corto plazo ($893.5M) de la empresa superan a sus pasivos a corto plazo ($92.0M).
Pasivo a largo plazo: NTLALos activos a corto plazo ($893.5M) superan a sus pasivos a largo plazo ($114.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: NTLA está libre de deudas.
Reducción de la deuda: NTLA no ha tenido ninguna deuda en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: NTLA tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: NTLA dispone de suficiente liquidez para 1.9 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 35.7% cada año.